Savara(US:SVRA) Prnewswire·2025-09-18 22:13Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [3][4]. Group 1: Allegations Against Savara - The complaint alleges that Savara and its executives made false and misleading statements regarding the MOLBREEVI BLA, specifically that it lacked sufficient information on chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, making previous public statements materially false and misleading [3]. Group 2: Stock Price Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 in Savara between March 7, 2024, and May 23, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Savara is November 7, 2025 [1].